Immune checkpoint inhibitors (ICIs) have revolutionized the treatment and care of patients with cancer owing to unique features, including the occurrence of the so-called immune-related adverse events (irAEs). A multidisciplinary team, possibly including a cardio-oncology specialist, is warranted to achieve a favorable patient outcome. Cardiovascular toxicity, especially myocarditis, emerged as a life-threatening irAE in the real-word setting, and the European Society of Cardiology has recently published the first guideline on cardio-oncology to increase awareness and promote a standardized approach to tackle this complex multimodal issue, including diagnostic challenges, assessment, treatment, and surveillance of patients with cancer receiving ICIs. In this article, through a question & answer format made up of case vignettes, we offer a clinically oriented overview on the latest advancements of ICI-related cardiovascular toxicity, focusing on myocarditis and associated irAEs (myositis and myasthenia gravis within the so-called overlap syndrome), with the purpose of assisting clinicians and healthcare professionals in daily clinical practice.

Raschi, E., Rossi, S., De Giglio, A., Fusaroli, M., Burgazzi, F., Rinaldi, R., et al. (2023). Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. DRUG SAFETY, 46(9), 819-833 [10.1007/s40264-023-01320-5].

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians

Raschi, Emanuel
Primo
;
Rossi, Simone;De Giglio, Andrea;Fusaroli, Michele;Burgazzi, Flavio;Potena, Luciano
2023

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment and care of patients with cancer owing to unique features, including the occurrence of the so-called immune-related adverse events (irAEs). A multidisciplinary team, possibly including a cardio-oncology specialist, is warranted to achieve a favorable patient outcome. Cardiovascular toxicity, especially myocarditis, emerged as a life-threatening irAE in the real-word setting, and the European Society of Cardiology has recently published the first guideline on cardio-oncology to increase awareness and promote a standardized approach to tackle this complex multimodal issue, including diagnostic challenges, assessment, treatment, and surveillance of patients with cancer receiving ICIs. In this article, through a question & answer format made up of case vignettes, we offer a clinically oriented overview on the latest advancements of ICI-related cardiovascular toxicity, focusing on myocarditis and associated irAEs (myositis and myasthenia gravis within the so-called overlap syndrome), with the purpose of assisting clinicians and healthcare professionals in daily clinical practice.
2023
Raschi, E., Rossi, S., De Giglio, A., Fusaroli, M., Burgazzi, F., Rinaldi, R., et al. (2023). Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. DRUG SAFETY, 46(9), 819-833 [10.1007/s40264-023-01320-5].
Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, Rita; Potena, Luciano
File in questo prodotto:
File Dimensione Formato  
Raschi et al., Drug Safety Cardiotoxicity ICI 2023.pdf

accesso aperto

Descrizione: Review Article
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 1.9 MB
Formato Adobe PDF
1.9 MB Adobe PDF Visualizza/Apri
40264_2023_1320_MOESM1_ESM.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 139.95 kB
Formato Adobe PDF
139.95 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/955316
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 11
social impact